Current Edition

Europe

CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD

Patient enrollment proceeding under amended protocol CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immuno...
Continue Reading →